BioCryst Pharmaceuticals’ (BCRX) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report released on Tuesday,Benzinga reports. The brokerage currently has a $11.00 price target on the biotechnology company’s stock, up from their previous price target of $10.00.

Several other brokerages have also recently weighed in on BCRX. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. JMP Securities reissued a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. Evercore ISI boosted their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Finally, Wedbush began coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday. They issued an “outperform” rating and a $15.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.57.

BioCryst Pharmaceuticals Trading Up 1.3 %

Shares of BCRX opened at $8.47 on Tuesday. The firm has a fifty day moving average price of $8.09 and a 200-day moving average price of $7.85. The firm has a market capitalization of $1.75 billion, a P/E ratio of -13.89 and a beta of 1.75. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The business’s quarterly revenue was up 40.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.28 earnings per share. Analysts predict that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Mackenzie Financial Corp increased its holdings in BioCryst Pharmaceuticals by 190.7% in the 4th quarter. Mackenzie Financial Corp now owns 84,662 shares of the biotechnology company’s stock worth $637,000 after buying an additional 55,535 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter worth $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of BioCryst Pharmaceuticals by 3.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock worth $3,016,000 after purchasing an additional 11,581 shares during the last quarter. Woodline Partners LP purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $3,385,000. Finally, Two Sigma Advisers LP raised its stake in shares of BioCryst Pharmaceuticals by 14.6% during the 4th quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company’s stock valued at $18,799,000 after buying an additional 318,800 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.